Pulmonary arterial hypertension (PAH) has a progressive, unremitting clinical course. Vasoreactivity testing (VdT) during right heart catheterisation (RHC) identifies a subgroup with excellent long-term response to calcium channel blockade (CCB). Reporting on these patients is limited. Established in 2011, the Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ) registry offers the opportunity to assess the frequency of VdT during RHC, treatment and follow up of PAH patients.
Registry data from 3,972 PAH patients with index RHC revealed 1,194 VdT appropriate patients. Data was analysed in three groups: 1) VdT+CCB+: VdT positive, CCB treated; 2) VdT+CCB-: VdT positive, no CCB prescribed, 3) VdT-/noVdT: VdT negative, or VdT not tested. Data was reviewed for adherence to guidelines, clinical response (World Health Organization functional class [WHO FC], 6-minute-walk-distance [6MWD], RHC), and outcomes (survival or lung transplantation).
Patients included had idiopathic (IPAH=1,087), heritable (HPAH=67) and drug or toxin-induced PAH (DPAH=40). A VdT was performed in 22% (268/1,194), with incomplete data in 26% (70/268); 28% (55/198) were VdT+. Analysis group allocation was: VdT+CCB+ (33/55), VdT+CCB- (22/55), VdT- (143)/noVdT (996). From patients with 1-year data VdT+CCB+ and VdT-/noVdT patients improved WHO FC, 6MWD and cardiac index (CI); VdT+CCB- data remained similar. Within the VdT+CCB+ group, 30% (10/33) were long-term CCB responders with a 100% 5-year survival; non-responders had a 61% survival at 5.4 years. Long-term responders were younger at diagnosis (40 yrs vs 54 yrs).
Use of VdT testing and documentation is poor in this contemporary patient cohort. Nonetheless, survival in VdT+CCB+ patients from the PHSANZ registry is excellent, supporting guidelines promoting VdT testing. Strategies to promote the use of VdT are warranted.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Heart, Lung and Circulation
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Advances in therapeutic interventions for patients with pulmonary arterial hypertension.Circulation. 2014; 130: 2189-2208
- Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.J Am Coll Cardiol. 2002; 40: 780-788
- Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.Eur Heart J. 2006; 27: 589-595
- The molecular targets of approved treatments for pulmonary arterial hypertension.Thorax. 2016; 71: 73-83
- Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.Circulation. 2002; 106: 1477-1482
- Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.Circulation. 2005; 111: 3105-3111
- Haemodynamic definitions and updated clinical classification of pulmonary hypertension.Eur Respir J. 2019; 53
- Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension.Eur Heart J. 2010; 31: 1898-1907
- Pulmonary vasoreactivity testing with adenosine predicts long term hemodynamic response to prostacyclin monotherapy, and prostacyclin and phosphodiesterase-5 inhibitor combination therapy in pulmonary arterial hypertension.JACC. 2018; 71: A1951https://doi.org/10.1016/S0735-1097(18)32492-6
- High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.Circulation. 1987; 76: 135-141
- Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).Circulation. 2010; 122: 164-172
- Comparison of drugs for pulmonary hypertension reversibility testing: a meta-analysis.Pulm Circ. 2013; 3: 406-413
- Risk stratification and medical therapy of pulmonary arterial hypertension.Eur Respir J. 2019; 53
- Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: the delay study.Pulm Circ. 2013; 3: 89-94
- Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry.Chest. 2009; 137: 376-387
- REVEAL: a contemporary US pulmonary arterial hypertension registry.Eur Respir Rev. 2012; 21: 8-18
- Epidemiology of pulmonary hypertension: new data from the Swiss registry.Swiss Med Wkly. 2008; 138: 379-384
- Collaborative registry of pulmonary hypertension in Argentina (RECOPILAR). Final analysis.Medicina (B Aires). 2021; 81: 180-190
- The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.N Engl J Med. 1992; 327: 76-81
- Clinical and instrumental characteristics of newly diagnosed patients with various forms of pulmonary hypertension according to the Russian National Registry.Biomed Res Int. 2020; 20206836973
- Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry.J Heart Lung Transplant. 2020; 39: 1435-1444
Published online: December 08, 2022
Accepted: September 1, 2022
Received in revised form: August 14, 2022
Received: January 27, 2022
© 2022 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.